3rd Quarter 2019 Quarterly Disclosure 13 November 2019 Marie - PowerPoint PPT Presentation

3rd Quarter 2019 Quarterly Disclosure 13 November 2019 Marie Roediger CFO 1

Gl Glob obally ally Po Positi sition oned ed for for 25 25 yea years rs Ni Nich che Play Player i er in Isoto n Isotope pe M Mark arket et Cancer Radiation Industrial Components Pharmaceuticals (RADIATION THERAPY) (RADIOPHARMA) ( ISOTOPE PRODUCTS ) Production Synthesis Implants LDR Devices Geräte Services Raw materials Applicators LDR API Trading Projects/ Devices HDR API Rohstoffe/ API Disposal Rohstoffe/ API Berlin EUR 33 Mio. EUR 20 Mio. EUR 80 Mio. 25% 16% 59% Strong 3rd Half Year 2019 with Revenues of € 133 Mio. (FY 2018: € 169 Mio.) Slides for Illustration – The spoken word shall be binding 2

From Ja Fro Janu nuary ary 1st 20 1st 2020 20: Medical Seg Med ical Segmen ment t Po Pool ol Cancer Radiation Industrial Components Pharmaceuticals (RADIATION THERAPY) (RADIOPHARMA) ( ISOTOPE PRODUCTS ) Production Synthesis Implants LDR Devices Geräte Services Raw materials Applicators LDR API Trading Projects/ Devices HDR API Rohstoffe/ API Disposal Engineering Rohstoffe/ API From 1.1.2020: MEDICAL Slides for Illustration – The spoken word shall be binding 3

800 800 Employ Employee ees (Head (Headco coun unts ts) ) 19 19 Site Sites s Wo World rldwide wide Result Q3-2019 (Mio. EUR) Revenues 133,2 Net Income 18,8 2% 2 6% 9% 44% 41% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA Slides for Illustration – The spoken word shall be binding 4

Reven Rev enue ues of of about about € 170 Mio. Mio. in in 2018 2018 18% organic growth in 2018 180 169 160 145 140 138 140 127 120 117 116 120 111 101 100 in Mio. EUR 80 71 60 54 50 42 36 40 33 31 29 24 20 10 8 6 6 4 2 1 0,13 0 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Incl. discontinued and continued operations Slides for Illustration – The spoken word shall be binding 5

Rev Reven enue ues pe per r Seg Segmen ment Q3-2019 Q3 2019 vs vs. . Q3 Q3-2018 2018 , Mio. Euro Total Revenues of 133,2 Mio. EUR in Q3-2019 ( Q3-2018: Euro 123,8 Mio. ) An increase of 8% in Q3-2019 Slides for Illustration – The spoken word shall be binding 6

Rev Reven enue ue Gro Growth wth all S all Seg egmen ments ts Q3 Q3-20 2019 19, , in Mio. Euro Slides for Illustration – The spoken word shall be binding 7

Isot Isotop ope e Pro Produ duct cts s Reve Revenu nue e Gr Growth owth Q3 Q3-20 2019 19, , in Mio. EUR Slides for Illustration – The spoken word shall be binding 8

Rad Radioph iophar arma ma Reve Revenu nue Gr e Growth owth Q3 Q3-20 2019 19, , in Mio. EUR Pharmazeutische Radioisotope Slides for Illustration – Only the spoken word shall be binding 9

Rad Radiation iation The Thera rapy py Reve Revenu nue e Gr Growth owth Q3 Q3-20 2019 19, , in Mio. EUR Slides for Illustration – The spoken word shall be binding 10

Q3-2019 Net Income (Earnings after tax and minorities) Distribution and Growth Slides for Illustration – The spoken word shall be binding 11

Net Net Inco Income me Q3 Q3-20 2019 19 vs vs. . Q3 Q3-20 2018 18, , in Mio. EUR Net Income of 18,8 Mio. EUR in Q3-2019 vs. 13,0 Mio. in Q3-2018 Slides for Illustration – The spoken word shall be binding 12

Net In Net Inco come me and and Sa Sales les Di Distribution stribution pe per Se r Segm gmen ent t in Q3 in Q3-2019 2019 Net income of 18,8 Mio. EUR Sales of 132,2 Mio. EUR 25% 44% 53% 60% 15% 3% Slides for Illustration – The spoken word shall be binding 13

Net Net Inco Income me Gro Growth wth all all Seg Segmen ments ts in Q3 in Q3-20 2019 19, , in Mio. EUR Slides for Illustration – The spoken word shall be binding 14

Q3-2019 Cashflow and Balance Sheet Slides for Illustration – The spoken word shall be binding 15

Balance Balan ce She Sheet et as as of of 30 30.09.20 .09.2019 19, , in Mio. EUR Cash 71 Equity 131 Recievables 25 Minority Interests 6 Inventory 31 Loans 18 Intangible Assets 70 Accruals/Provisions 66 Fixed Assets 38 Other Short Term Payables 31 Others 25 Other Long Term Payables 6 Total Activ 259 Total Passiv 259 • Cash and cash equivalents at period end of 71 Mio. EUR • Debt Free (except accounted leasing according to IFRS 16) • Equity Ratio of 53% Slides for Illustration – The spoken word shall be binding 16

Cashflow Cashflow in in Q3 Q3-20 2019 19, , in Mio. EUR EBITDA of 36,6 Mio. EUR Slides for Illustration – The spoken word shall be binding 17

Net Net Liqu Liquidity idity in in Q3 Q3-2019, 2019, in Mio. EUR +10 mm EUR for treasury shares 80 80 70 70 60 60 50 50 In Mio. EUR 40 40 30 30 20 20 10 10 0 0 2014 2015 2016 2017 2018 Q3-2019 Liquidity 22 31 37 58 54 71 Debt 19 16 12 2 0 0 Net Liquidity 3 15 25 56 54 71 Slides for Illustration – The spoken word shall be binding 18

Sha Share re Per Performa formanc nce e and and Dividen Dividend d in in EUR/Share EUR/Share Dividende in EUR / Aktie EUR/Aktie 180 1,20 160 1,10 140 1,00 120 100 0,90 1,2 80 0,80 60 0,70 40 0,60 0,8 20 0,66 0,60 0,60 0,60 0,50 0 2014 2015 2016 2017 2018 2019 Slides for Illustration – The spoken word shall be binding 19

Str Strat ateg egy / Gr / Growt owth h Opp Oppor ortu tunities nities From tigers, dragons and other animals 20

Since Since 2014 2014 Incr Increa easing sing M&A M&A Act Activities ivities Isotop • Bayer/ ALGETA 2,1 Mrd. USD Ra-223 – (2014) • IPSEN/ OPS 0,1 Mrd. USD Ge-68 – 2015 • NOVARTIS/ AAA Ge-68 4,0 Mrd. USD – (2017) • NOVARTIS/ Endocyte Lu-177 2,1 Mrd. USD – 2017 • GCP/ SIRTEX Y-90 1,4 Mrd. USD – June 2018 • Boston Scientific/ BTG 4,2 Mrd. USD Y-90 – November 2018 • Bracco/ Blue Earth F-18 0,5 Mrd. EUR – April 2019 Slides for Illustration – The spoken word shall be binding

EANM EANM Con Confi firms rms: : No No End End to to M&A M&A Act Activities ivities Isotop • Bayer/ ALGETA 2,1 Mrd. USD Ra-223 – (2014) • IPSEN/ OPS 0,1 Mrd. USD Ge-68 – 2015 • NOVARTIS/ AAA Ge-68 4,0 Mrd. USD – (2017) • NOVARTIS/ Endocyte Lu-177 2,1 Mrd. USD – 2017 • GCP/ SIRTEX Y-90 1,4 Mrd. USD – Juni 2018 • Boston Scientific/ BTG 4,2 Mrd. USD Y-90 – November 2018 • Bracco/ Blue Earth F-18 0,5 Mrd. EUR – April 2019 Slides for Illustration – The spoken word shall be binding

Sev Sever eral al Tre Trend nds s co come me together together 1. Precision Oncology – A tiger by the tail Germanium-68 for Diagnosis – Lutetium-177 for Therapy 2. China – Liver carcinoma = high priority in health policy – Boom of Yttrium-90 providers for radioembolisation products (SIRTEX, BTG, providers of generics) The Dragon 3. Swallows/ e.g. Alpha-Emitter – BAYER = forerunner – Encouraging investment rounds The Swallow Slides for Illustration – The spoken word shall be binding 23

Pre Precision cision Onc Oncolog ology, , st stil ill l at at the the beginning beginning DIAGNOSIS (Ge-68) THERAPY (Lu-177) Advantages Neuroendocrine tumors • Therapy only for patients who respond to the diagnostic – avoids unnecessary expenses – avoids unnecessary Prostate, patient stress Renal cancer Non-Hodgkin-Lymphoma Gastro • Strengthens nuclear physicians as a distribution channel Slides for Illustration – The spoken word shall be binding 24

Exp Expan ansion sion of of Indica Indication tion is is li like kely ly to to come come Clinical studies with Lu-177 acc. to FDA, Phase II or higher, as of May 2019 25 https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply Slides for Illustration – The spoken word shall be binding

EZA EZAG G well well pos positioned itioned in in the the diag diagno nosis sis (Ge (Ge-68) 68) • Generators Therapeutic arm (Lutetium) • Synthesis modules is also making progress: • Work benches • Technology validated • Complete isotope production • Supply chain established • First deliveries to customers have been made Slides for Illustration – The spoken word shall be binding 26

YTTR YTTRIUM IUM-90 90 The Chinese Health Market is growing Slides for Illustration – The spoken word shall be binding 27

What‘s Dr Driving iving the the Dr Drag agon on? ? Reimbu Reimburs rseme ement nt and and Liver Liver Can Cance cer China 280,000 men 100,000 women ~380,000 cases per year (!) Reimbursement China ~ 11,000 US$/ patient Age-standardized incidence rates of hepatocellular carcinoma per 100,000 populations at risk, in different regions of world (Source: GLOBOCAN 2002). Slides for Illustration – The spoken word shall be binding 28